Recurrent Rhabdomyolysis after Kidney Transplant in Adult-Onset VLCAD Deficiency

Year 2025, Volume: 14 Issue: 3 , 230 - 233 , 30.12.2025

Beyhan Güvercin , Büşra Korkmaz Baki

https://doi.org/10.47493/abantmedj.1705660

https://izlik.org/JA43LJ77ED

Abstract

Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency is a hereditary disorder of mitochondrial long-chain fatty acid oxidation. It is a syndrome characterized by rhabdomyolysis, muscle necrosis, and release of intracellular muscle components into the circulation. A 29-year-old male patient with hypertension, arrhythmia, and preemptive renal transplantation history was admitted to our clinic with complaints of recurrent hematuria attacks, body pain, and dizziness. No erythrocytes were observed in the microscopic field of urine sediment. In genetic analysis, a homozygous mutation was detected in the ACADVL gene in the NM_000018.4 C.1500_1502del CCT p. L502del variation, and VLCAD deficiency was diagnosed. We planned to discuss the case with the literature in order to emphasize that metabolic myopathies should also be evaluated in the etiology of patients who develop acute renal failure presenting with recurrent non-traumatic exercise-associated rhabdomyolysis.

Keywords

Rhabdomyolysis , Very Long-Chain Acyl-CoA Dehydrogenase , Kidney Transplant

References

• Marsden D, Bedrosian CL, Vockley J. Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders. Genet Med. 2021;23(5):816–829.
• Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: pathophysiology and diagnosis. Eur J Intern Med. 2007;18(2):90–100.
• Bhai S. Rhabdomyolysis: clinical manifestations and diagnosis. In: UpToDate [Internet]. Waltham, MA: UpToDate Inc.; 2025 Feb. Available from: https://www.uptodate.com/contents/rhabdomyolysis-clinical-manifestations-and-diagnosis
• Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore). 2005;84(6):377–385.
• Fatehi F, Okhovat AA, Nilipour Y, Mroczek M, Straub V, Töpf A, et al. Adult-onset very-long-chain acyl-CoA dehydrogenase deficiency (VLCADD). Eur J Neurol. 2020;27(11):2257–2266.
• Andresen BS, Olpin S, Poorthuis BJ, Scholte HR, Vianey-Saban C, Wanders R, et al. Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet. 1999;64(2):479–494.
• Ahmed A, de Buitleir C, Elsheik N, Sweeney M. Very long-chain acyl-CoA dehydrogenase deficiency presenting as rhabdomyolysis. Ir Med J. 2022;115(3):565.
• Scalco RS, Gardiner AR, Pitceathly RD, Zanoteli E, Becker J, Holton JL, et al. Rhabdomyolysis: a genetic perspective. Orphanet J Rare Dis. 2015;10:51.
• Lucia A, Martinuzzi A, Nogales-Gadea G, Quinlivan R, Reason S; International Association for Muscle Glycogen Storage Disease study group. Clinical practice guidelines for glycogen storage disease V and VII (McArdle disease and Tarui disease) from an international study group. Neuromuscul Disord. 2021;31(12):1296–1310.
• Vockley J. Long-chain fatty acid oxidation disorders and current management strategies. Am J Manag Care. 2020;26(7 Suppl):S147–S154.